Follow The Filings

RYTM Rhythm Pharmaceuticals

Rhythm Pharmaceuticals earnings company data as of 6:51 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by RYTM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RYTM insider trades
  • None no insider bought on the open market
  • $931K sold by 1 insider outside a trading plan
  • $39.2M sold by 8 insiders under 10b5-1 plans
  1. David P Meeker CEO
    Planned sale
    $5.1M 50,000 shares at $102.67 17% of stake
    Traded Sep 14 Filed Sep 14
    ↗
  2. Hunter C Smith CFO
    Planned sale
    $6.6M 62,774 shares at $105.46 36% of stake
    Traded Aug 31 Filed Sep 1
    ↗
  3. Joseph Shulman Chief Technical Officer
    Planned sale
    $608K 5,079 shares at $119.75 24% of stake
    Traded Aug 13 Filed Aug 17
    ↗
  4. Alastair Garfield Chief Scientific Officer
    Planned sale
    $913K 7,763 shares at $117.57 77% of stake
    Traded Aug 13 Filed Aug 17
    ↗
  5. Jennifer Kayden Lee EVP, Head of North America
    Planned sale
    $8.9M 75,834 shares at $117.38 100% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  6. Yann Mazabraud EVP, Head of International
    Planned sale
    $6.6M 57,000 shares at $116.15 51% of stake
    Traded Aug 12 Filed Aug 14
    ↗
  7. Lynn A. Tetrault Director
    Planned sale
    $3.7M 37,000 shares at $100.32 84% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  8. Christopher Paul German Corporate Controller & CAO
    Sale
    $428K 4,643 shares at $92.21 100% of stake
    Traded May 15 Filed May 19
    ↗
  9. Christopher Paul German Corporate Controller & CAO
    Sale
    $503K 5,614 shares at $89.56 97% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  10. Hunter C Smith CFO
    Planned sale
    $806K 7,954 shares at $101.31 6.7% of stake
    Traded Feb 17–19 Filed Feb 19
    ↗
  11. Hunter C Smith CFO
    Planned sale
    $709K 7,071 shares at $100.21 5.6% of stake
    Traded Feb 10–12 Filed Feb 12
    ↗
  12. Hunter C Smith CFO
    Planned sale
    $703K 6,628 shares at $106.03 5% of stake
    Traded Feb 4–5 Filed Feb 6
    ↗
  13. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $372K 3,350 shares at $111.00 14% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  14. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $352K 3,350 shares at $105.00 14% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
    ↗
  15. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $2.3M 22,866 shares at $99.00 52% of stake
    Traded Nov 7–10 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 38 option exercises, 9 share withholdings for taxes, and 2 other transactions.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.